Chemotherapeutische Optionen bei Lebermetastasen

Vol. 19, No. 4, 2003

Free Abstract Article (PDF 83 KB)

Multimodale Therapie von Lebermetastasen
Editors: E. Klar, Rostock; Y. Yamamoto, Akita; M. Birth, Lübeck

Main Theme · Hauptthema

Chemotherapeutische Optionen bei Lebermetastasen
G. Folprecht, C.-H. Köhne

Chir Gastroenterol 2003;19:364-369 (DOI: 10.1159/000076073)

Summary

Chemotherapeutic Options of Liver Metastases

Chemotherapy of liver metastases of colorectal cancer has been developed during the last years. The use of a combination therapy of 5-fluorouracil and irinotecan or oxaliplatin induces tumor responses in 50% of the patients and enables neoadjuvant treatment of nonresectable metastasis. Following secondary resection, prognosis does not differ from that of patients with initially resectable liver metastases. In palliative treatment, overall survival time has been prolonged to a median of 20 months due to the more effective chemotherapy. The benefit of adjuvant chemotherapy following resection of liver metastasis is not proven.

This journal is part of the third subject package of the Karger

Journal Archive Collection

Information on packages (PDF)
Free sample issues

For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.